Are the following areas under pre-clinical development, plus the GBM delivery system under re-design, what you are considering is the IP we are developing (in collab or otherwise)... that will underpin future patent applications by CHM?
- Undisclosed Next-Gen CAR NK study in blood and/or solid tumours (CHM 3301)
- CAR NK-cell study with CDH17 in solid tumours (CHM 2301)
- CAR NK-cell with CLTX (CHM 1301)
- CAR T-cell with CLTX in solid tumours (CHM 1101)
- CAR T-cell with CDH17 in solid tumours (CHM 2101)
If so, then some data readouts from any one of the above studies in the lab/s would be welcome. Pre-clinical data always seems to excite the masses, Bec!!! There is a lot of potential asset value there for CHM to trot out!
Chimeric: Media Thread, page-821
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $14.18M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.6¢ | $9.273K | 548.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 1365817 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 24633 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |